Last updated: July 3, 2026
Vifor v. Mylan Laboratories (3:20-cv-01647): Litigation summary, claims at issue, and exclusivity impact
Executive summary
Vifor (International) AG sued Mylan Laboratories Ltd. in the District Court for the District of Delaware under Hatch-Waxman, alleging infringement of Vifor patents tied to its branded product in the iron deficiency treatment space and seeking to block Mylan’s proposed generic entry. The case is docketed 3:20-cv-01647, filed in 2020. The litigation posture and commercial risk hinge on (1) whether the asserted Vifor patents remained enforceable through the relevant Orange Book and statutory exclusivity windows and (2) the claim construction and validity outcomes for the asserted patent family.
Actionable bottom line: without a verified record of the asserted patent numbers, Mylan’s ANDA paragraph (I/II/III/IV), and the court’s dispositive rulings (motions-to-dismiss, claim construction, summary judgment, or settlement filings), a complete litigation analysis cannot be produced.
What patents were asserted in Vifor (International) AG v. Mylan Laboratories Ltd. 3:20-cv-01647?
A correct litigation analysis requires the exact asserted patent list and the specific claims Vifor asserted.
Which Vifor patent numbers were at issue
No asserted patent numbers are provided in the prompt. A complete summary depends on the specific United States patents listed in the complaint and served infringement contentions.
What drug product and ANDA link were alleged
A full claim-to-product mapping requires the NDA/ANDA reference listed drug (RLD), the active ingredient salt form, and the Orange Book reference used in the infringement pleading.
How strong was Vifor’s infringement case in 3:20-cv-01647?
Patent infringement strength is determined by claim construction, the technology described in the ANDA, and the court’s findings on equivalence or literal infringement.
Claim construction milestones
Key inputs include:
- Markman dates and construed terms
- Whether the court adopted Vifor’s proposed construction
- Whether Mylan’s non-infringement arguments prevailed for each asserted claim
These are not included in the prompt.
Core infringement theories usually tested
In Hatch-Waxman disputes, courts commonly test:
- Anticipation of formulation constraints
- Equivalence of preparation/manufacturing steps
- Method-of-use or dosing regimen boundaries
A reliable analysis needs the actual theory pled and litigated.
How did Mylan challenge validity in 3:20-cv-01647?
A validity analysis must cover the exact combination of defenses and the asserted statutory bases.
Invalidity grounds
A full treatment requires knowing which of the following Mylan raised:
- 35 U.S.C. § 101 (eligibility)
- 35 U.S.C. § 102 (novelty)
- 35 U.S.C. § 103 (obviousness)
- 35 U.S.C. § 112 (written description and enablement, definiteness)
- Prosecution history estoppel and claim scope limits
Prior art relied on by Mylan
Without the disclosed prior art references and the court’s ruling, it is not possible to quantify or score validity strength.
What was the Orange Book status of Vifor’s patents in this case?
Orange Book status controls statutory exclusivity leverage and the practical value of asserted patents.
Which listed patents and exclusivity types
A complete answer requires:
- Orange Book listed patent numbers (and expiration dates)
- Whether the patents were tied to exclusivity types (e.g., 5-year, 7-year, 180-day exclusivity)
- Whether any patents were delisted before adjudication
How ANDA paragraph affected exclusivity timelines
The ANDA paragraph (I/II/III/IV) determines whether FDA approval is blocked and how quickly generic entry can occur after a final court outcome.
When does Vifor’s exclusivity or patent term expire relative to Mylan’s generic launch risk?
Exclusivity timelines drive settlement posture and entry incentives.
Patent expiration dates that controlled settlement economics
A litigation-and-risk analysis requires:
- The expiration schedule for each asserted patent
- Any terminal disclaimers
- PTA (patent term adjustment) applied dates
- Whether additional continuations extended enforceable term
No patent-by-patent expiration data is provided in the prompt.
Did Mylan file a Paragraph IV ANDA, and what did it certify?
To assess litigation posture, the analysis must identify:
- Whether Mylan certified to each Orange Book patent as “Paragraph IV”
- Whether Mylan used “Paragraph III” or “Paragraph I”
- Whether the FDA approval was conditioned on court outcomes
These facts are not in the prompt.
What generic entry risks existed for Mylan if Vifor lost?
If the asserted patents were held invalid or not infringed, the generic path accelerates subject to:
- Eligibility for 180-day exclusivity (if Mylan was the first filer)
- Any triggering settlements or non-use agreements
- FDA review timing for labeling changes
A risk assessment needs the ANDA status and procedural posture, neither of which are specified.
What patent litigation outcomes occurred in 3:20-cv-01647 (motions, rulings, trial, settlement)?
A litigation summary must include:
- Whether the case reached a claim construction order
- Whether any patents were found not infringed
- Whether any patents were found invalid
- Whether the case ended in settlement and, if so, the key terms
The prompt does not provide docket outcomes, orders, or settlement dates.
What settlement terms are relevant to generic timing and market entry?
In Hatch-Waxman disputes, settlements often include:
- Dates of generic launch
- Stipulated dismissal with prejudice
- “Covenant not to sue” agreements
- License terms, if any
- Terms governing exclusivity triggers
No settlement information is provided in the prompt.
How does this case compare with other Vifor vs. generic litigation in iron deficiency drugs?
Comparative analysis requires knowing:
- The specific Vifor product and patent family at issue
- The outcome and enforceability trends across the same patent estates
- Whether courts consistently upheld certain claim types (composition vs. method-of-use vs. dosing regimen)
Without the asserted product/patent estate, a valid comparison cannot be executed.
Key Takeaways
- A litigation summary for Vifor (International) AG v. Mylan Laboratories Ltd., 3:20-cv-01647 requires the asserted patent numbers, ANDA paragraph certifications, and the court’s dispositive orders or settlement terms.
- Those litigation-critical facts are not present in the prompt, so a complete, accurate infringement-and-validity analysis cannot be produced.
FAQs
- What does an ANDA Paragraph IV filing mean for a generic launch date in Hatch-Waxman cases?
- How do claim construction outcomes typically affect infringement results in patent suits tied to FDA drug approvals?
- What validity defenses under §§ 101, 102, 103, and 112 most often decide Hatch-Waxman patent cases?
- How do Orange Book listing and patent delisting affect the scope of Hatch-Waxman litigation?
- What provisions in Hatch-Waxman settlements most directly determine when a generic can enter the market?
References
No sources are provided in the prompt.
